Analyst Reco. Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Real-time Estimate Cboe BZX Other stock markets 03:25:39 2024-05-02 pm EDT			5-day change	1st Jan Change
15.04 ^USD	-1.02%		+2.28%	-10.68%

Apr. 10	Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	MT
Apr. 04	Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	Apr. 10	MT
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	Mar. 28	MT
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target	Mar. 14	MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23	Mar. 07	MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating	Mar. 01	MT
Oppenheimer Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $30 Price Target	Dec. 21	MT
Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $24 From $22, Maintains Buy Rating	23-06-20	MT
Truist Securities Adjusts Catalyst Pharmaceuticals' Price Target to $22 From $18, Keeps Buy Rating	23-01-19	MT
Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $18 From $17, Maintains Buy Rating	22-12-21	MT
HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $24 From $18, Keeps Buy Rating	22-12-21	MT
Piper Sandler Adjusts Catalyst Pharmaceuticals Price Target to $20 From $18, Maintains Overweight Rating	22-12-20	MT
ANALYST RECOMMENDATIONS : Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...	22-08-24
Roth Capital Downgrades Catalyst Pharmaceuticals to Neutral From Buy; Price Target is $15.50	22-08-24	MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $18 From $15, Maintains Overweight Rating	22-08-11	MT
Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $17 From $12, Maintains Buy Rating	22-08-11	MT
HC Wainwright Raises Catalyst Pharmaceuticals' Price Target to $18 From $12, Keeps Buy Rating	22-08-11	MT
Piper Sandler Adjusts Price Target on Catalyst Pharmaceuticals to $16 From $9, Reiterates Overweight Rating	22-08-11	MT
History shows stocks can weather rate hike cycle	22-03-16	RE
HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $12 From $9, Maintains Buy Rating	22-02-08	MT
CATALYST PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Catalyst Pharmaceuticals to $11 From $8, Maintains Overweight Rating	21-05-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 10:44 am EST